Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Sep 30, 2026
Reporting period
Not applicable
Filed with the SEC
Oct 2, 2026
CFOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001104659-26-113361
Filed / recorded
Oct 2, 2026, 9:15 PM UTC
Added to OQRO
Oct 6, 2026, 11:36 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Verastem, Inc.
Issuer CIK
1526119
Ticker
VSTM
Reporting person
Daniel Calkins
Relationship
Officer
Officer title
Chief Financial Officer
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Sep 30, 2026
Transaction code
A
Shares / units
8,333
Price per share
$0.00
Acquired / disposed
Disposed (D)
Shares owned after
126,347
Ownership form
Direct
Amendment
No
Footnotes from the filing
The reported securities were subject to a performance restricted stock units ("RSU") award that was granted on January 21, 2026. 106,893 RSUs vested on September 30, 2026, upon the Issuer's Compensation Committee of the board of directors determining the performance criteria related to certain clinical development goals had been achieved.